D.A. Davidson & CO. increased its stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Get Rating) by 3.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 13,811 shares of the exchange traded fund’s stock after purchasing an additional 410 shares during the quarter. D.A. Davidson & CO.’s holdings in SPDR S&P Biotech ETF were worth $1,146,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Larson Financial Group LLC raised its holdings in shares of SPDR S&P Biotech ETF by 92.7% in the fourth quarter. Larson Financial Group LLC now owns 3,076 shares of the exchange traded fund’s stock valued at $255,000 after acquiring an additional 1,480 shares in the last quarter. Spire Wealth Management increased its holdings in SPDR S&P Biotech ETF by 2.3% during the fourth quarter. Spire Wealth Management now owns 13,875 shares of the exchange traded fund’s stock valued at $1,152,000 after buying an additional 314 shares during the period. Abundance Wealth Counselors bought a new position in SPDR S&P Biotech ETF in the fourth quarter worth approximately $1,611,000. SG Americas Securities LLC lifted its holdings in SPDR S&P Biotech ETF by 141.4% during the fourth quarter. SG Americas Securities LLC now owns 60,215 shares of the exchange traded fund’s stock worth $4,998,000 after buying an additional 35,275 shares during the period. Finally, MGO Private Wealth LLC raised its holdings in SPDR S&P Biotech ETF by 53.1% in the fourth quarter. MGO Private Wealth LLC now owns 14,455 shares of the exchange traded fund’s stock worth $1,200,000 after purchasing an additional 5,016 shares in the last quarter.
SPDR S&P Biotech ETF Trading Down 0.7 %
Shares of SPDR S&P Biotech ETF stock opened at $78.80 on Friday. The firm’s 50 day simple moving average is $79.10 and its two-hundred day simple moving average is $81.62. The firm has a market capitalization of $7.41 billion, a price-to-earnings ratio of 11.47 and a beta of 1.00. SPDR S&P Biotech ETF has a 12-month low of $61.78 and a 12-month high of $95.18.
SPDR S&P Biotech ETF Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Featured Stories
- Get a free copy of the StockNews.com research report on SPDR S&P Biotech ETF (XBI)
- 10 E-commerce Stocks to Consider for Long-Term Buys
- Joby Aviation Extends Deal With Air Force, Analysts Maintain Hold
- Meta’s Earnings; Time To Buckle Up
- Why Invest in High-Yield Dividend Stocks?
- Dividend Prince Automatic Data Processing Hits Bottom
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Get Rating).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
